The study enrolled 334 patients who had suffered what the researchers classify as high-risk non-disabling ischemic cerebrovascular events, abbreviated HR-NICE. This category covers transient ischemic attacks and minor strokes that do not leave patients disabled but carry a high probability of recurrence. The danger window is brutally short: the risk of another vascular event is highest within the first days and weeks after the initial episode, which is precisely when early neurological deterioration tends to strike. Patients were enrolled within 24 hours of symptom onset — a demanding logistical requirement that reflects how rapidly the therapeutic window closes. Once enrolled, they were randomly assigned in a one-to-one ratio to one of two dual antiplatelet regimens: low-dose ticagrelor at 60 milligrams twice daily plus aspirin, or clopidogrel plus aspirin.

The logic behind the comparison rests on a well-known weakness of clopidogrel. The drug is a prodrug, meaning it must be converted by liver enzymes into its active form before it can inhibit platelets. The critical enzyme, CYP2C19, is encoded by a gene that varies widely between individuals. People carrying so-called loss-of-function alleles — a variant that is especially common in East Asian populations, affecting a majority of Chinese patients — convert clopidogrel poorly or not at all. For these patients, standard clopidogrel-based therapy offers substantially weaker platelet inhibition, and previous studies have linked poor clopidogrel response to early neurological deterioration after acute ischemic stroke. Ticagrelor, by contrast, is a reversible P2Y12 receptor antagonist that does not require metabolic activation, so its antiplatelet effect is essentially independent of CYP2C19 genotype.

This pharmacological distinction has already reshaped stroke care in China. The CHANCE-2 trial, published in the New England Journal of Medicine in 2021, showed that in patients carrying CYP2C19 loss-of-function alleles, ticagrelor plus aspirin outperformed clopidogrel plus aspirin in preventing recurrent stroke within 90 days. But CHANCE-2 required rapid genotyping to identify carriers — a capability that many hospitals, particularly in resource-limited settings, simply do not have. The new trial was designed with this gap in mind. Rather than genotyping patients and treating only those with the resistant variant, the investigators asked a more pragmatic question: does low-dose ticagrelor beat clopidogrel in an unselected HR-NICE population, where a large proportion of patients would be expected to carry loss-of-function alleles?

The answer was a clear yes. Early neurological deterioration within seven days — defined as an increase of at least two points on the National Institutes of Health Stroke Scale, or a one-point increase in the motor subscore compared with baseline — occurred in 10.8 percent of patients receiving ticagrelor plus aspirin, compared with 22.2 percent of those receiving clopidogrel plus aspirin. That corresponds to a relative risk of 0.55, with a 95 percent confidence interval of 0.33 to 0.92 and a p-value of 0.023. In plain terms, the ticagrelor regimen roughly halved the odds that a patient’s neurological condition would worsen in the critical first week. The trial used an intention-to-treat analysis, the most conservative approach, and its open-label design with blinded endpoint adjudication means that while treating physicians knew which drugs patients received, the researchers assessing outcomes did not — a design that minimizes bias in the primary result.

The benefits extended well beyond the first week. At 90-day follow-up, 92.8 percent of patients in the ticagrelor group had achieved an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale, the standard measure of post-stroke disability. In the clopidogrel group, the figure was 80.8 percent — a statistically significant difference, with a relative risk of 1.13 and a p-value of 0.002. The rate of major ischemic vascular events within 90 days also trended in favor of ticagrelor, at 6.6 percent versus 10.8 percent, though this difference did not reach statistical significance (relative risk 0.54; p = 0.085), likely reflecting the relatively small number of events in a trial of this size.

Just as important as the efficacy signal was the safety profile, because the perennial concern with intensified antiplatelet therapy is bleeding. Dual antiplatelet regimens walk a narrow line: they must suppress platelet aggregation enough to prevent clot propagation and recurrence, but not so much that spontaneous hemorrhage becomes a hazard. In this trial, any bleeding events occurred in 6.0 percent of the ticagrelor group versus 4.2 percent of the clopidogrel group — a difference that was neither statistically significant (p = 0.563) nor clinically alarming, particularly since all bleeding events in both groups were classified as mild. Rates of adverse events overall (12.6 percent versus 10.2 percent) and serious adverse events (0.6 percent versus 1.8 percent) were similarly balanced between the groups. The low 60-milligram twice-daily dose of ticagrelor, rather than the 90-milligram dose used in cardiac patients, appears to be the key to achieving potent platelet inhibition while keeping bleeding in check.

The trial’s design details reinforce the credibility of these findings. It was registered prospectively with the Chinese Clinical Trial Registry in February 2023, conducted across multiple centers, and approved by the ethics committee of the First Affiliated Hospital of Dalian Medical University, with all patients or their legal representatives providing written informed consent. The investigators adhered to the Declaration of Helsinki and Good Clinical Practice guidelines. The primary endpoint — early neurological deterioration — is a mechanistically meaningful outcome, because it captures the dynamic process of thrombus growth and new clot formation in the vulnerable cerebral circulation, rather than merely counting later recurrent strokes. By targeting this early window, the regimen intervenes at the moment when platelet-rich thrombi are most actively propagating.

Why does the result matter globally, and not only in China? The CYP2C19 loss-of-function variant is most prevalent in East Asian populations, but it is common elsewhere too, and clopidogrel resistance is a recognized problem wherever the drug is used. Moreover, the trial’s most practical implication is precisely that it does not require genotyping. The authors conclude that the regimen may provide a safe and effective alternative antiplatelet strategy for preventing early neurological deterioration in institutions lacking rapid genotyping facilities — a description that fits the majority of stroke centers worldwide. A physician confronting a patient with a high-risk minor stroke or TIA can start low-dose ticagrelor plus aspirin immediately, without waiting for genetic test results that may take days or simply be unavailable.

Cautions remain, as they always do with a single trial. The study was conducted in China, the sample size of 334 patients is modest, and the open-label design, while mitigated by blinded endpoint assessment, cannot eliminate all performance bias. The trend toward fewer ischemic vascular events at 90 days did not reach statistical significance, and longer-term outcomes beyond three months were not assessed. Broader international replication, ideally in populations with different baseline risks and genetic backgrounds, would strengthen the evidence base. Still, the magnitude of the effect on early deterioration — the single most feared event in the days after a minor stroke — combined with a clean bleeding profile, makes this one of the more consequential antiplatelet findings in recent stroke research. For patients in the fragile hours after a warning stroke, a cheap, widely available, genotype-independent drug combination that halves the risk of getting worse is exactly the kind of pragmatic advance that changes clinical practice.

Subject of Research: Low-dose ticagrelor plus aspirin versus clopidogrel plus aspirin for preventing early neurological deterioration after high-risk non-disabling ischemic cerebrovascular events

Article Title: Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial

Article References: Liu, J., Cao, H., Wang, M., Jiao, Y., Zhou, R., Tang, Y., Chen, R., Liu, X., Shen, J., Li, D., Tian, W., Gong, X., Zhang, B., Liu, Y., & Ji, X. (2026). Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial. Journal of Neurology, 273(10), Article 568. https://doi.org/10.1007/s00415-026-14094-4

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14094-4

Keywords: ticagrelor, aspirin, clopidogrel, early neurological deterioration, minor stroke, transient ischemic attack, dual antiplatelet therapy, CYP2C19, randomized clinical trial, stroke prevention, P2Y12 inhibitor, functional outcome